News

ReFlow Medical Inc., SpeX shapeable support catheter, FDA

ReFlow Medical Inc. announced U.S. Food and Drug Administration (FDA) clearance for commercialization of their SpeX shapeable support catheter in the United States for use in the peripheral...

Oxford clinical study, American Heart Association, abdominal aortic aneurism

Oxford University researchers presented data that reveal the extent to which smoking causes silent but deadly damage to health at the annual scientific meeting of the American Heart Association (...

VIVA Physicians, a not-for-profit organization in the field of vascular medicine and intervention, announced late-breaking clinical trial results VIVA 14, an annual multidisciplinary...

Covidien releases 12-month results of the DEFINITIVE AR study, the first randomized study designed to identify the clinical benefits of plaque removal using directional atherectomy ...

VIVA, VIVA Physicians, Peripheral, Carotid Artery Device, clinical trial results

Viva Physicians, a not-for-profit organization in the field of vascular medicine and intervention, announce clinical trial results and other new happenings at Viva '14, hosted in Las Vegas,...

Shockwave, lithoplasty, lithotripsy

Shockwave Medical announced positive clinical results from Disrupt PAD, a single-arm multicenter study evaluating the safety and utility of Lithoplasty balloon catheters for the treatment of...

For the treatment of peripheral artery disease in leg arteries above the knee, the IN.PACT Admiral ...

Cardiovascular Systems Inc. received the CE Mark for its Stealth 360º Orbital Atherectomy System (OAS). Stealth 360º is a percutaneous OAS that is indicated to treat patients who suffer from...

Food and Drug Administration gave 510(k) clearance for the HawkOne directional atherectomy system. The latest addition to Covidien’s directional atherectomy portfolio, the HawkOne system...

Shockwave Medical announced that the company will present clinical results from DISRUPT PAD, a single-arm multicenter study evaluating the safety and utility of Lithoplasty balloon catheters for...

Metro Health (Michigan) cardiovascular specialist Jihad Mustapha, M.D., is one of the first physicians in the United States to use a new medical device to treat peripheral artery disease (PAD).

Everflex stent, Covidien, ev3

The U.S Food and Drug Administration (FDA) cleared the EverFlex Self-Expanding Peripheral Stent System and outlined...

Medtronic IN.PACT Admiral Drug Coated Balloon Peripheral Artery Disease Treatmen

Presented for the first time at the 2014 Transcatheter Cardiovascular Therapeutics (TCT) conference, the latest clinical and economic data on the IN.PACT Admiral drug-coated balloon (DCB)...

More than 40 percent of Americans aged 40 and older have experienced one or more of the most common symptoms[1] of peripheral arterial disease (PAD).

The first large prospective study to examine the effectiveness of laser atherectomy in the treatment of femoropopliteal in-stent restenosis (ISR) found that the procedure combined with...

Covidien TurboHawk Clinical Study Directional Atherectomy Effective PAD Therapy

Directional atherectomy is safe and effective as a frontline therapy for the treatment of peripheral arterial disease (PAD), according to a landmark Covidien study published online in the ...

Directional atherectomy is safe and effective as a frontline therapy for the treatment of peripheral arterial disease (PAD), according to a landmark Covidien study published online today in the...

Teleflex Inc.’s subsidiary Hotspur Technologies Inc. received U.S. Food and Drug Administration (FDA) 510(k) clearance to market the Arrow GPSCath Balloon Dilatation Catheters designed for use...

Biotronik Enrollment Completion SFA Arm BIOFLEX-I Study Pulsar-18 4-French

Biotronik announced the completion of patient enrollment in the superficial femoral artery (SFA) arm of its BIOFLEX-I clinical trial, an U.S. Food and Drug Administration (FDA)-approved...

Biotronik BIOLUX 4Ever Clinical Trial Pulsar-18 SES Passeo-18 Lux DRB PAD Cath

Biotronik announced that the first patient has been enrolled in the investigator-initiated BIOLUX 4EVER trial.